Last reviewed · How we verify
Nitrofurantoin or Trimethoprim or Cefalexin
Nitrofurantoin, Trimethoprim, and Cefalexin are marketed antibiotics produced by Newcastle-upon-Tyne Hospitals NHS Trust, with a key composition patent expiring in 2028. The primary strength of these drugs lies in their established presence in the antibiotic market, supported by their broad spectrum of activity against common bacterial infections. The primary risk is the potential increase in generic competition following the patent expiry in 2028, which could erode market share and revenue.
At a glance
| Generic name | Nitrofurantoin or Trimethoprim or Cefalexin |
|---|---|
| Also known as | Macrodantin |
| Sponsor | Newcastle-upon-Tyne Hospitals NHS Trust |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Clinical Trial of Extended (High) Treatment Dose Antibiotics in Combination With Methenamine Hippurate Compared to the Standard of Care (Either Prophylactic (Low) Dose Antibiotic Treatment or Methenamine Hippurate) in Females With Chronic Urinary Tract Infection (PHASE2)
- Randomized Trial of Culture Directed Versus Empiric Antibiotics for Urinary Tract Infections in Older Women (PHASE4)
- Endourology Disease Group Excellence (EDGE) Consortium: Antibiotics (Abx) for Percutaneous Nephrolithotomy (PCNL) Part 2 (NA)
- Prophylactic Antibiotic Administration for Bladder OnabotulinumtoxinA Injection (PHASE4)
- Struvite Stones Antibiotic Study (PHASE4)
- Electronic Prescription Data to Improve Primary Care Prescribing (NA)
- Patients Response to Early Switch To Oral:Osteomyelitis Study (EARLY_PHASE1)
- Antibiotic Prophylaxis for Clean Intermittent Catheterisation (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: